- Conditions
- Cancer
- Interventions
- forodesine hydrochloride
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 1,033
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- ERC1671, GM-CSF, Cyclophosphamide, Oral Control (Sucrose pill), Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)), Bevacizumab/Bevacizumab Biosimilar
- Drug
- Lead sponsor
- Epitopoietic Research Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 3
- States / cities
- Orange, California • Boston, Massachusetts
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm
- Interventions
- Anti-Endoglin Chimeric Monoclonal Antibody TRC105, Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 308
- States / cities
- Little Rock, Arkansas • Fullerton, California • Orange, California + 219 more
- Conditions
- Malignant Glioma, WHO Grade III or IV Recurrent Glioma
- Interventions
- Topotecan, Gadolinium DTPA, Cleveland Multiport Catheter
- Drug · Device
- Lead sponsor
- Michael Vogelbaum, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Giant Cell Glioblastoma, Gliosarcoma, Oligodendroglioma, Recurrent Glioblastoma, Small Cell Glioblastoma
- Interventions
- autologous dendritic cells pulsed with tumor lysate antigen Vaccine, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
- Biological · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Astrocytoma, Grade III
- Interventions
- NOVOTTF-200A
- Device
- Lead sponsor
- Daniela A. Bota
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Brain Tumor, High Grade Glioma
- Interventions
- topotecan, Cleveland Multiport Catheter
- Drug · Device
- Lead sponsor
- Michael Vogelbaum, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Recurrent Diffuse Pontine Gliomas
- Interventions
- nimotuzumab (anti EGFR humanized monoclonal antibody)
- Biological
- Lead sponsor
- YM BioSciences
- Industry
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 10
- States / cities
- Denver, Colorado • Washington D.C., District of Columbia • Gainesville, Florida + 6 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- semaxanib
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more
- Conditions
- Glioblastoma, GBM
- Interventions
- AZD1775
- Biological
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Recurrent Glioblastoma
- Interventions
- Dendritic Cell Tumor Cell Lysate Vaccine, Pembrolizumab, Placebo Administration, Poly ICLC
- Biological · Other · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Grade IV Glioma, Grade IV Astrocytoma, Glioblastoma Multiforme
- Interventions
- TVI-Brain-1
- Biological
- Lead sponsor
- TVAX Biomedical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- Kansas City, Missouri • St Louis, Missouri • Dallas, Texas + 1 more
- Conditions
- Recurrent Glioblastoma
- Interventions
- panobinostat
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma
- Interventions
- Infigratinib
- Drug
- Lead sponsor
- Helsinn Healthcare SA
- Industry
- Eligibility
- 3 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Washington D.C., District of Columbia • Miami, Florida + 3 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- porfimer sodium, adjuvant therapy, conventional surgery
- Drug · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Recurrent Childhood Medulloblastoma, Recurrent Ependymoma, Recurrent Medulloblastoma
- Interventions
- Laboratory Biomarker Analysis, Natural Killer Cell Therapy
- Other · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Recurrent or Progressive Malignant Glioma
- Interventions
- ANG1005
- Drug
- Lead sponsor
- Angiochem Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Detroit, Michigan • New York, New York + 3 more
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Interventions
- cilengitide, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Watertown, Massachusetts
- Conditions
- Recurrent Glioblastoma IDH Wildtype
- Interventions
- D2C7-IT, 2141 V11
- Drug
- Lead sponsor
- Darell Bigner
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- irinotecan hydrochloride, temozolomide, vincristine sulfate
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Orange, California • Stanford, California + 13 more
- Conditions
- Glioblastoma, Glioma
- Interventions
- Ascorbic Acid, Bevacizumab, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Dietary Supplement · Biological · Other
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Recurrent Glioblastoma Multiforme, Recurrent Gliosarcoma
- Interventions
- temozolomide and bevacizumab
- Drug
- Lead sponsor
- Center for Neurosciences, Tucson
- Other
- Eligibility
- 18 Years to 83 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Brain Tumor, Central Nervous System Tumor
- Interventions
- radiation therapy
- Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 20 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2018
- U.S. locations
- 127
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 109 more
- Conditions
- Brain Tumor, Malignant Neoplasm of Fourth Ventricle of Brain
- Interventions
- Ommaya Reservoir, Methotrexate, Leucovorin
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 22 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 2
- States / cities
- Houston, Texas